Cresco Labs is a Chicago-based, publicly traded cannabis company founded in 2013. It cultivates and manufactures cannabis, distributes branded products to company-owned and independent stores, and operates dispensaries under the Sunnyside name. “Cresco” is also the flagship product label, so shoppers may encounter the same word on a package and in the parent company’s corporate name.
Origins and ownership
Charlie Bachtell co-founded Cresco and serves as chief executive. Joe Caltabiano was also a co-founder and served as president before leaving in 2020. The company combines cultivation, manufacturing, wholesale distribution and retail within state-regulated systems. Cannabis products cannot be moved through ordinary interstate commerce, so each market relies on locally licensed facilities even when the consumer brand is shared across states.
The brand portfolio
The portfolio includes Cresco, High Supply, FloraCal Farms, Good News, Wonder Wellness Co., Mindy’s and Remedi. Cresco spans flower, live-resin vapor products, pre-rolls and concentrates. High Supply emphasizes accessible and larger-format products, while Good News and Mindy’s are associated with edibles. Remedi covers measured oral, topical and extract formats. Selection and formulation vary by state license and facility.
Where it operates
Sunnyside is the retail side of the company. Store menus include Cresco-owned brands alongside products from other licensed producers. Inventory, medical or adult-use status, taxes and purchase limits depend on location. A Sunnyside listing therefore does not mean the item was necessarily manufactured by Cresco, and a Cresco product sold through an independent dispensary remains part of the same wholesale brand system.
Brand names may remain consistent while strain selection, formulation, package size and manufacturing license change by state. Adults and registered patients should use their state’s licensed retailer system, then check the physical package for producer, ingredients, batch number, testing identifier and dates. Public-company financial reporting provides useful corporate context, but it does not replace product-level information for a specific purchase.
Recognition
For the quarter ended June 30, 2026, Cresco reported $173 million in revenue, $15 million in net income and $40 million in adjusted EBITDA. Adjusted EBITDA is a non-GAAP measure and should be read with the reconciliation in the company’s release. Operating updates included Kentucky product sales, Pennsylvania integration work and additions to the Ohio retail footprint.
Recent activity
On September 2, 2026, Cresco announced the acquisition of nine operating Pennsylvania dispensaries for $50 million. The transaction expanded its retail position in a state where it already sold wholesale products. The announcement is a dated corporate event, not a permanent store-count guarantee: openings, closures, acquisitions and licensing changes can alter the footprint after a reporting period.
Company programs
Cresco also operates the SEED initiative, short for Social Equity & Educational Development, and has described research and environmental programs. Those efforts sit alongside the commercial platform rather than changing the legal status of its products. Corporate and investor announcements should be read with their stated dates, while consumers can use local licensed menus for the latest product and store information.
Brand focus
From Chicago, IL, Cresco Labs builds its operating identity around multi-state cannabis operator, cannabis manufacturing and sunnyside dispensaries. multi-state cannabis operator anchors that model, while cannabis manufacturing and sunnyside dispensaries connects the production work to the products and licensed markets carrying the name.